409 related articles for article (PubMed ID: 10409442)
21. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
Giltnane JM; Murren JR; Rimm DL; King BL
Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
[TBL] [Abstract][Full Text] [Related]
22. Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas.
Fan QB; Bian ML; Huang SZ; Lang JH; Ma J; Liu WS; Xu XY
Chin Med J (Engl); 1994 Aug; 107(8):589-93. PubMed ID: 7805442
[TBL] [Abstract][Full Text] [Related]
23. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
[TBL] [Abstract][Full Text] [Related]
24. How is Her-2/neu status established when Her-2/neu and chromosome 17 centromere are both amplified?
Press MF
Am J Clin Pathol; 2006 Nov; 126(5):673-4. PubMed ID: 17050063
[No Abstract] [Full Text] [Related]
25. HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters.
Cianciulli AM; Guadagni F; Marzano R; Benevolo M; Merola R; Giannarelli D; Marandino F; Vocaturo G; Mariani L; Mottolese M
J Exp Clin Cancer Res; 2003 Jun; 22(2):265-71. PubMed ID: 12866577
[TBL] [Abstract][Full Text] [Related]
26. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
27. Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization.
Parrella P; Caballero OL; Sidransky D; Merbs SL
Invest Ophthalmol Vis Sci; 2001 Jul; 42(8):1679-84. PubMed ID: 11431428
[TBL] [Abstract][Full Text] [Related]
28. Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer.
Mark HF; Samy M; Santoro K; Mark S; Feldman D
Exp Mol Pathol; 2000 Feb; 68(1):65-9. PubMed ID: 10640455
[TBL] [Abstract][Full Text] [Related]
29. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays.
Mayr D; Kanitz V; Amann G; Engel J; Burges A; Löhrs U; Diebold J
Histopathology; 2006 Jan; 48(2):149-56. PubMed ID: 16405663
[TBL] [Abstract][Full Text] [Related]
30. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
31. [The relation between prognosis and amplification of the c-erB-2 (HER-2/neu) proto-oncogene in ovarian carcinomas].
Fan QB; Bian ML; Huang SZ
Zhonghua Yi Xue Za Zhi; 1994 Nov; 74(11):683-5, 710. PubMed ID: 7866905
[TBL] [Abstract][Full Text] [Related]
32. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
[TBL] [Abstract][Full Text] [Related]
33. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
[TBL] [Abstract][Full Text] [Related]
35. Dual fluorescence in situ hybridization in detection of HER-2 oncogene amplification in primary hepatocellular carcinoma.
Huang TJ; Huang BJ; Liang QW; Huang CW; Fang Y
Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):62-8. PubMed ID: 14969840
[TBL] [Abstract][Full Text] [Related]
36. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers.
Park K; Kwak K; Kim J; Lim S; Han S
Hum Pathol; 2005 Jun; 36(6):634-9. PubMed ID: 16021569
[TBL] [Abstract][Full Text] [Related]
37. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
38. A molecularly genetic determination of prognostic factors of the prostate cancer and their relationships to expression of protein p27kip1.
Dvorácková J; Uvírová M
Neoplasma; 2007; 54(2):149-54. PubMed ID: 17319789
[TBL] [Abstract][Full Text] [Related]
39. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
40. Her-2/neu gene amplification in paraffin-embedded tissue sections of meningioma patients.
Ozer O; Sahin FI; Aydemir F; Ozen O; Yilmaz Z; Altinörs N
Turk Neurosurg; 2009 Apr; 19(2):135-8. PubMed ID: 19431122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]